The role of hospital payments in the adoption of new medical technologies: an international survey of current practice

Published on Apr 1, 2015in Health Economics, Policy and Law
· DOI :10.1017/S1744133114000358
Corinna Sorenson14
Estimated H-index: 14
(LSE: London School of Economics and Political Science),
Michael Drummond73
Estimated H-index: 73
(Ebor: University of York)
+ 2 AuthorsCéu Mateus11
Estimated H-index: 11
(University of Lisbon)
This study examined the role of prospective payment systems in the adoption of new medical technologies across different countries. A literature review was conducted to provide background for the study and guide development of a survey instrument. The survey was disseminated to hospital payment systems experts in 15 jurisdictions. Fifty-one surveys were disseminated, with 34 returned. The surveys returned covered 14 of the 15 jurisdictions invited to participate. The majority (71%) of countries update the patient classification system and/or payment tariffs on an annual basis to try to account for new technologies. Use of short-term separate or supplementary payments for new technologies occurs in 79% of countries to ensure adequate funding and facilitate adoption. A minority (43%) of countries use evidence of therapeutic benefit and/or costs to determine or update payment tariffs, although it is somewhat more common in establishing short-term payments. The main barrier to using evidence is uncertain or unavailable clinical evidence. Almost three-fourths of respondents believed diagnosis-related group systems incentivize or deter technology adoption, depending on the particular circumstances. Improvements are needed, such as enhanced strategies for evidence generation and linking evidence of value to payments, national and international collaboration and training to improve existing practice, and flexible timelines for short-term payments. Importantly, additional research is needed to understand how different payment policies impact technology uptake as well as quality of care and costs.
  • References (50)
  • Citations (7)
📖 Papers frequently viewed together
43 Citations
2 Citations
10 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Francesc Cots Reguant (Ciber)H-Index: 2
#2Pietro ChiarelloH-Index: 7
Last. Xavier Castells (Autonomous University of Barcelona)H-Index: 33
view all 4 authors...
Knee replacement is a common surgical procedure performed to relieve pain and disability from degenerative osteoarthritis. This study evaluates the ability of ten European diagnosis-related group (DRG) systems to explain variations in costs or in length of stay for knee replacements. We assessed three different models in predicting variation of cost and length of stay. The first model, MD, included only DRG groups as explanatory variables; the second, MP, used a set of patient-level variables; a...
8 CitationsSource
#1Andrew Street (Ebor: University of York)H-Index: 30
#2Conrad Kobel (Innsbruck Medical University)H-Index: 10
Last. Josselin Thuilliez (EHESP)H-Index: 8
view all 4 authors...
We set out an analytical strategy to examine variations in resource use, whether cost or length of stay, of patients hospitalised with different conditions. The methods are designed to evaluate (i) how well diagnosis-related groups (DRGs) capture variation in resource use relative to other patient characteristics and (ii) what influence the hospital has on their resource use. In a first step, we examine the influence of variables that describe each individual patient, including the DRG to which ...
51 CitationsSource
#1Reinhard Busse (National Institute for Health and Welfare)H-Index: 3
#2Alexander GeisslerH-Index: 14
Last. Hanna Rättö (National Institute for Health and Welfare)H-Index: 6
view all 11 authors...
SUMMARY This study contributes to the literature on the performance of diagnosis-related groups (DRGs) for acute myocardial infarction (AMI) patients by evaluating in nine countries the factors—in addition to DRGs—that affect costs or length of stay and comparing the variation that can be explained with or without DRGs. We evaluate whether the existing DRGs for AMI patients would benefit from additional patient-related and treatment-related factors that are found in administrative data across co...
19 CitationsSource
#1Alexander Geissler (Technical University of Berlin)H-Index: 14
#1Reinhard Busse (Technical University of Berlin)H-Index: 48
Last. Andrew StreetH-Index: 30
view all 3 authors...
This paper assesses the variations in costs and length of stay for hip replacement cases in Austria, England, Estonia, Finland, France, Germany, Ireland, Poland, Spain and Sweden and examines the ability of national diagnosis-related group (DRG) systems to explain the variation in resource use against a set of patient characteristic and treatment specific variables. In total, 195 810 cases clustered in 712 hospitals were analyzed using OLS fixed effects models for cost data (n = 125 698) and neg...
28 CitationsSource
#1Kalipso ChalkidouH-Index: 23
#2Sean TunisH-Index: 46
Last. Merrick ZwarensteinH-Index: 55
view all 5 authors...
There is a growing appreciation that our current approach to clinical research leaves important gaps in evidence from the perspective of patients, clinicians, and payers wishing to make evidence-based clinical and health policy decisions. This has been a major driver in the rapid increase in interest in comparative effectiveness research (CER), which aims to compare the benefits, risks, and sometimes costs of alternative health-care interventions in ‘the real world’. While a broad range of exper...
108 CitationsSource
#1David Scheller-Kreinsen (Technical University of Berlin)H-Index: 10
#2Wilm Quentin (Technical University of Berlin)H-Index: 19
Last. Reinhard Busse (Technical University of Berlin)H-Index: 48
view all 3 authors...
Objectives: To assess how diagnosis-related group– based (DRG-based) hospital payment systems in 12 European countries participating in the EuroDRG project pay and incorporate technological innovation. Methods: A standardized questionnaire was used to guide comprehensive DRG system descriptions. Researchers from each country reviewed relevant materials to complete the questionnaire and drafted standardized country reports. Two characteristics of DRG-based hospital payment systems were identified...
43 CitationsSource
#1Corinna Sorenson (LSE: London School of Economics and Political Science)H-Index: 14
#2Rosanna Tarricone (Bocconi University)H-Index: 22
Last. Michael DrummondH-Index: 73
view all 4 authors...
Medical devices pose unique challenges for economic evaluation and associated decision-making processes that differ from pharmaceuticals. We highlight and discuss these challenges in the context of cardiac device therapy, based on a systematic review of relevant economic evaluations. Key challenges include practical difficulties in conducting randomized clinical trials, allowing for a ‘learning curve’ and user characteristics, accounting for the wider organizational impacts of introducing new de...
36 CitationsSource
#1Giulia Cappellaro (Bocconi University)H-Index: 6
#2Simone Ghislandi (Bocconi University)H-Index: 12
Last. Eugenio Anessi-Pessina (UCSC: Catholic University of the Sacred Heart)H-Index: 11
view all 3 authors...
In the last decade the pace of innovation in medical technology has accelerated: hence the need to better identify and understand the real forces behind the adoption and diffusion of medical technology innovations in clinical practice. Among these forces, financial incentives may be expected to play a major role. The purpose of this paper was to assess the influence of financing mechanisms for new medical devices and correlated procedures on their diffusion. The analysis was carried out in the I...
31 CitationsSource
#1Reinhard BusseH-Index: 48
#2Alexander GeisslerH-Index: 14
Last. Miriam M. WileyH-Index: 11
view all 4 authors...
182 Citations
#1Glenn Robert ('KCL': King's College London)H-Index: 33
#2Trisha Greenhalgh (UCL: University College London)H-Index: 82
Last. R Peacock (Middlesex University)H-Index: 4
view all 4 authors...
Objective: To explore what is known about organizational processes that determine whether (and the extent and rate at which) new non-pharmaceutical technologies are adopted and assimilated into routine health care. Methods: Electronic searching of four databases, hand searching of six journals and electronic citation tracking searches of three key research papers. A narrative synthesis was conducted. Results: Ninety-nine empirical studies and seven narrative overviews informed the findings. The ...
80 CitationsSource
Cited By7
#1Patricia Ex (Technical University of Berlin)H-Index: 1
#2Verena Vogt (Technical University of Berlin)H-Index: 6
Last. Cornelia Henschke (Technical University of Berlin)H-Index: 8
view all 4 authors...
: Most hospital payment systems based on diagnosis-related groups (DRGs) provide payments for newly approved technologies. In Germany, they are negotiated between individual hospitals and health insurances. The aim of our study is to assess the functioning of temporary reimbursement mechanisms. We used multilevel logistic regression to examine factors at the hospital and state levels that are associated with agreeing innovation payments. Dependent variable was whether or not a hospital had succe...
1 CitationsSource
#1Patricia Ex (Technical University of Berlin)H-Index: 1
#2Cornelia Henschke (Technical University of Berlin)H-Index: 8
This paper empirically investigates the impact of additional reimbursement instruments on the diffusion of new technologies in inpatient care. Using 2010–2014 German panel data on hospital level for every patient undergoing coronary angioplasty, this study examines the utilisation of drug-eluting balloon catheters (DEB) over time while additional payment instruments changed. Hypothesising that the utilisation of DEB increased abruptly when a new reimbursement instrument came into force, we estim...
#1Zachary RappH-Index: 1
#2Ryan D. EgelandH-Index: 1
Last. Frank S. DavidH-Index: 7
view all 3 authors...
Background: Under the inpatient prospective payment system (IPPS), Medicare assigns hospital discharges to medical severity-adjusted diagnosis related groups (MS-DRGs), and determines a fixed payment amount for each discharge based on its MS-DRG that is adjusted annually based on providers’ reported costs. Trends in these capitated reimbursement rates may affect the incentive for manufacturers to develop drugs and devices used in inpatient care, as well as the predilection of customers (hospital...
#1Aleksandra Torbica (Bocconi University)H-Index: 19
#2Rosanna Tarricone (Bocconi University)H-Index: 22
Last. Michael Drummond (Ebor: University of York)H-Index: 73
view all 3 authors...
10 CitationsSource
#1Susanne Felgner (Technical University of Berlin)H-Index: 2
#2Patricia Ex (Technical University of Berlin)H-Index: 1
Last. Cornelia Henschke (Technical University of Berlin)H-Index: 8
view all 3 authors...
Abstract Objectives To foster value-based pricing and coverage with evidence development in Germany, certain new diagnostic and treatment methods have been subject to a benefit assessment since 2016 to determine their reimbursement. Although this is a paradigm shift, the German approach is limited to some few specific technologies for which reimbursement is requested. As physicians encounter this regulatory instrument, the aim of the study was to understand physicians' decision making regarding ...
1 CitationsSource
#1Patricia Ex (Technical University of Berlin)H-Index: 1
#2Susanne Felgner (Technical University of Berlin)H-Index: 2
Last. Cornelia Henschke (Technical University of Berlin)H-Index: 8
view all 3 authors...
Zusammenfassung Hintergrund Die Erstattung neuer Gesundheitstechnologien wird nicht selten uber Sozialgerichte eingeklagt. Dabei liegt es nahe, dass gerichtliche Entscheidungen auch Einzelfallentscheidungen der Krankenkassen und damit den Patientenzugang insgesamt beeinflussen. Ziel der Studie Ziel ist anhand von Rechtsprechungen zu identifizieren, welche Technologien wiederholt eingeklagt wurden und ob diese zu einer Kostenerstattung fuhrten. Dabei liegt der Fokus auf Unterschieden zwischen Sek...
1 CitationsSource
#1Alessandra Ferrario (LSE: London School of Economics and Political Science)H-Index: 14
Background Little comparative evidence is available on utilisation of cancer medicines in different countries and its determinants. The aim of this study was to develop a statistical model to test the correlation between utilisation and possible determinants in selected European countries.